Neumega

Neumega Oprelvekin Genetics Institute Prevention of severe chemotherapy-induced thrombocytopenia... 

Neumega) -constitutional symptoms—headache, fever, malaise... 

Neumega is the tradename given to the IL-ll-based product approved for the prevention of thrombocytopenia. The product is produced in engineered E. coli cells and is presented as a purified product in freeze-dried format. Excipients include phosphate buffer salts and glycine. It is reconstituted (with water for injections) to a concentration of 5 mg ml-1 before s.c. administration. 

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. 

Filgrastim [G-CSF] (Neupogen) Oprelvekin (Neumega) Pegfilgrastim (Neulasta)... 

Platelets, small cell fragments produced from bone marrow cells, work with the cascade of proteins in the formation of blood clots. If platelet counts are low, leaks in blood vessels that would normally be small can lead to the loss of large amoimts of blood. Certain chemotherapy drugs knock out the production of the cells that produce platelets. Oprelvekin (Neumega ), produced in E. coli, stimulates bone marrow to produce that very important type of cell. 

Neumega (rIL-11) Approved (1997) Prevention of chemotherapy-induced thrombocytopenia Genetics Institute... 

Dosage form Neumega is available for injection in single-use vials containing 5 mg of oprelvekin as a sterile lyophilized powder. It is reconstituted by the addition of sterile water for injection. 

Route of administration Neumega should be administered subcutaneously as a single injection in the abdomen, thigh, or hip (or upper arm if not self-injecting). In... 

Pharmacokinetics According to product label, analysis of data from a study in healthy men and women who received intravenous and subcutaneous Neumega revealed that following subcutaneous administration absorption is the rate-limiting step. Hence the elimination rate constants... 

E. Therapeutic response The primary end point of one randomized, placebo-controUed trial was whether the patient required one or more platelet transfusions in the subsequent chemotherapy cycle. More patients avoided platelet transfusion in the Neumega arm (28%) than in the placebo arm (7%). 

Parenteral (Iron dextran) (InFeD, DexFerrum) 50 mg elemental iron/mL Parenteral (Sodium ferric gluconate complex) (Ferrlecit) 12.5 mg elemental iron/mL Parenteral (Iron sucrose) (Venofer) 20 mg elemental iron/mL Oprelvekin (IL-11) (Neumega)... 

NEUMEGA (Oprelvekin) Wyeth-Ayerst [E. coli expressed recombinant thrombotic growth factor]... 

---